Our ability to prognosticate the clinical course of patients with cancer has historically been
limited to clinical, histopathological, and radiographic features. It has long been clear …

Purpose There is a discrepancy in the efficacy of abiraterone acetate for overall survival
(OS) in patients with high-risk metastatic hormone-sensitive prostate cancer (mHSPC). This …

The endocrine-related cancers and hormones are undoubtedly highly interconnected. How
hormones support or repress tumor induction and progression has been extensively …

Purpose Apalutamide plus androgen-deprivation therapy (ADT) has been approved for
treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC) based on …

Androgen receptor (AR), a ligand-activated transcription factor, is a master regulator in the
development and progress of prostate cancer (PCa). A major challenge for the clinically …

Background Although prostate cancer is a very common form of malignancy in men, the
clinical significance of androgen deprivation therapy (ADT) with abiraterone acetate versus …

Regulation of ubiquitination is associated with multiple processes of tumorigenesis and
development, including regulation of the tumor immune microenvironment. Deubiquitinating …

Abstract Background Prostate cancer (PCa) is the most frequently diagnosed cancer in men
in Europe. The impact of PCa natural history and therapeutic management on the outcomes …

Simple Summary Longer survival times for prostate cancer patients due to efficient
treatments consisting of local radiotherapy, prostatectomy and androgen-deprivation …

Context Several studies have investigated selection and sequencing of systemic agents to
manage recurrent prostate cancer following local definitive treatment. Objective To define …